Table 3 In clinical trials/Novel Targets
From: Potential new targets for drug development in severe asthma
Specific target | Drug | Biomarkers | Outcomes | Potential Adverse Events | References |
|---|---|---|---|---|---|
CRTH2 | OC000459 (Phase 2) | None | Improved FEV1 and quality of life scores | Cardiovascular and cerebrovascular events; helminthic and viral infections | Barnes 2012 [31] Pettipher 2014 [32] |
| Â | BI 671800 (Phase 2) | None | Mixed results for FEV1 improvement Mixed results for asthma control scores | Cardiovascular and cerebrovascular events; helminthic and viral infections | Â |
|  | QAW039/Fevipiprant (Phase 3) | ↑Sputum eosinophils (≥2% for Gonem et al.) | Decreased sputum eosinophils Mixed results for FEV1 improvement Mixed results for asthma control scores | Cardiovascular and cerebrovascular events; helminthic and viral infections | Gonem 2016 [39] Erpenbeck 2016 [37] Bateman 2017 [38] |
|  | ARRY-602 (Phase 2) | ↑Th2 associated biomarkers | Improved FEV1, asthma control and quality of life score | Cardiovascular and cerebrovascular events; helminthic and viral infections | Wenzel 2014 |
TSLP | AMG 157/Tezepelumab (Phase 2) | None | Reduced early and late response (FEV1 decrease) to allergen challenge Decreased exacerbations Improved FEV1 Decreased blood eosinophils, FeNO, and total IgE | Cardiovascular and cerebrovascular events; skin infections; Guillain-Barre | Gauvreau 2014 [48] Corren 2017 [49] |
CXCR2/IL-8 | SCH527123/Navarixin (Phase 2) | ↑Sputum neutrophils (>  40%) | Decreased sputum neutrophils Trend towards improved asthma control | Nasopharyngitis; neutropenia | Nair 2012 [73] |
|  | AZD5069 (Phase 2) | ↑Blood neutrophils (≥ 2.7 × 109/L) | No difference in exacerbations | Nasopharyngitis; neutropenia | O’Byrne 2016 [74] |
IL-33 | REGN3500 (Phase 1) ANB020 (Phase 2) | Results pending | Â | Cardiovascular and cerebrovascular events; helminthic and viral infections | Â |
IL-25 | Â | No biologics in human trials yet | Â | Cardiovascular and cerebrovascular events; helminthic and viral infections | Â |
IL-17A | CCJM112 (Phase 2) | Low IgE and Blood Eosinophils | Â | Â | Â |